Mannan-MUC1 - Pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma

Clinical Cancer Research

Volumn 12, Issue 3 I, 2006, Pages 869-877

  Loveland, Bruce E ^a   Zhao, Anne ^a   White, Shane ^a   Gan, Hui ^a   Hamilton, Kate ^a   Xing, Pei Xiang ^a   Pietersz, Geoffrey A ^a   Apostolopoulos, Vasso ^a   Vaughan, Hilary ^a   Karanikas, Vaios ^a   Kyriakou, Peter ^a   McKenzie, Ian F C ^a   Mitchell, Paul L R ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; MANNAN; MUCIN 1;

ADENOCARCINOMA; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANTIBODY RESPONSE; ANXIETY DISORDER; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; IMMUNE RESPONSE; INJECTION SITE HYPERSENSITIVITY; KIDNEY CARCINOMA; LEUKAPHERESIS; LOW BACK PAIN; LUNG NON SMALL CELL CANCER; MALE; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; UTERINE TUBE CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOTHERAPY; INTERFERON TYPE II; LEUKAPHERESIS; MALE; MANNANS; MIDDLE AGED; MUCINS; PHENOTYPE; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 32944475905     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1574     Document Type: Article

References (38)

1. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
2. Lodge PA, Jones LA, Bader RA, et al. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000;60:829-33.
3. Panelli MC, Wunderlich J, Jeffries J, et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 2000;23:487-98.
4. Mersey P, Menzies SW, Halliday GM, et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 2004;53:125-34.
5. Chen Q, Jackson H, Parente P, et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A 2004;101:9363-8.
6. Maraskovsky E, Sjolander S, Drane DP, et al. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1 + tumors. Clin Cancer Res 2004;10:2879-90.
7. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
8. Rieser C, Ramoner R, Holtl L, et al. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol Int 1999;63:151-9.
9. Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998;90:1894-900.
10. Morse MA, Nair SK, Mosca PJ, et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003;21:341-9.
11. O'Rourke MG, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003;52:387-95.
12. Homma S, Matai K, Irie M, et al. Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinoma. J Gastroenterol 2003;38:989-94.
13. Mocellin S. Cancer vaccines: the challenge of developing an ideal tumor killing system. Front Biosci 2005;10:2285-305.
14. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4:45-60.
15. Apostolopoulos V, Pietersz GA, Loveland BE, et al. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci U S A 1995;92:10128-32.
16. Apostolopoulos V, Pietersz GA, Gordon S, et al. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur J Immunol 2000;30:1714-23.
17. Karanikas V, Hwang LA, Pearson J, et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 1997;100:2783-92.
18. Karanikas V, Lodding J, Maino VC, McKenzie IF. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin Cancer Res 2000;6:829-37.
19. Karanikas V, Thynne G, Mitchell P, et al. Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection. J Immunother 2001;24:172-83.
20. Sandrin MS, Vaughan HA, Xing PX, McKenzie IF. Natural human anti-Galα(1,3)Gal antibodies react with human mucin peptides. Glycoconj J 1997;14:97-105.
21. Apostolopoulos V, Osinski C, McKenzie IF. MUC1 cross-reactive Galα(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat Med 1998;4:315-20.
22. Xing PX, Apostolopoulos V, Pietersz G, McKenzie IF. Anti-mucin monoclonal antibodies. Front Biosci 2001;6:01284-95.
23. Apostolopoulos V, Xing P, Trapani J, McKenzie I. Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein. Br J Cancer 1993;67:713-20.
24. Apostolopoulos V, Pietersz G, McKenzie I. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 1996;14:930-8.
25. Siddiqui J, Abe M, Hayes D, et al. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc Natl Acad Sci U S A 1988;85:2320-3.
26. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
27. Clay TM, Hobeika AC, Mosca PJ, et al. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 2001;7:1127-35.
28. Hock BD, Starling GC, Daniel PB, Hart DN. Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunology 1994;83:573-81.
29. Apostolopoulos V, Barnes N, Pietersz GA, McKenzie IF. Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine 2000;18:3174-84.
30. Schmittel A, Keilholz U, Thiel E, Scheibenbogen C. Quantification of tumor-specific T lymphocytes with the ELISPOT assay. J Immunother 2000;23:289-95.
31. Speiser DE, Pittet MJ, Guillaume P, et al. Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-γ ELISPOT assays for patient immune monitoring. J Immunother 2004;27:298-308.
32. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003;15:138-47.
33. Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with Melanoma. J Immunol 2005;175:6169-76.
34. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
35. Rustin GJ, Bast RC, Jr., Kelloff GJ, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004;10:3919-26.
36. Mukherjee P, Ginardi AR, Madsen CS, et al. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj J 2001;18:931-42.
37. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest 2003;21:873-86.
38. Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004;53:275-306.